Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.

van Gastel MDA, Edwards ME, Torres VE, Erickson BJ, Gansevoort RT, Kline TL.

J Am Soc Nephrol. 2019 Jul 3. pii: ASN.2018090902. doi: 10.1681/ASN.2018090902. [Epub ahead of print]

PMID:
31270136
2.

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators.

Kidney Int. 2019 Jul;96(1):159-169. doi: 10.1016/j.kint.2018.11.044. Epub 2019 Mar 9.

PMID:
30898339
3.

A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.

Simms RJ, Doshi T, Metherall P, Ryan D, Wright P, Gruel N, van Gastel MDA, Gansevoort RT, Tindale W, Ong ACM.

Eur Radiol. 2019 Aug;29(8):4188-4197. doi: 10.1007/s00330-018-5918-9. Epub 2019 Jan 21.

PMID:
30666443
4.

Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan.

Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT.

Am J Kidney Dis. 2019 Mar;73(3):354-362. doi: 10.1053/j.ajkd.2018.09.016. Epub 2018 Dec 19.

PMID:
30578153
5.

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators.

JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870.

6.

Case report: a thiazide diuretic to treat polyuria induced by tolvaptan.

Kramers BJ, van Gastel MDA, Meijer E, Gansevoort RT.

BMC Nephrol. 2018 Jul 3;19(1):157. doi: 10.1186/s12882-018-0957-7.

7.

The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.

D'Agnolo HMA, Casteleijn NF, Gevers TJG, de Fijter H, van Gastel MDA, Messchendorp AL, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JFM, Zietse R, Gansevoort RT, Drenth JPH.

Am J Nephrol. 2017;46(3):239-248. doi: 10.1159/000479436. Epub 2017 Sep 8.

PMID:
28881341
8.

T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease.

van Gastel MDA, Messchendorp AL, Kappert P, Kaatee MA, de Jong M, Renken RJ, Ter Horst GJ, Mahesh SVK, Gansevoort RT; DIPAK Consortium.

Abdom Radiol (NY). 2018 May;43(5):1215-1222. doi: 10.1007/s00261-017-1285-2.

9.

Polycystic Kidney Disease and the Vasopressin Pathway.

van Gastel MDA, Torres VE.

Ann Nutr Metab. 2017;70 Suppl 1:43-50. doi: 10.1159/000463063. Epub 2017 Jun 15. Review.

10.

Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease.

Casteleijn NF, van Gastel MD, Blankestijn PJ, Drenth JP, de Jager RL, Leliveld AM, Stellema R, Wolff AP, Groen GJ, Gansevoort RT; DIPAK Consortium.

Kidney Int. 2017 Apr;91(4):972-981. doi: 10.1016/j.kint.2016.12.007. Epub 2017 Jan 31.

PMID:
28159317
11.

Effects of potassium supplementation on markers of osmoregulation and volume regulation: results of a fully controlled dietary intervention study.

Riphagen IJ, Gijsbers L, van Gastel MD, Kema IP, Gansevoort RT, Navis G, Bakker SJ, Geleijnse JM.

J Hypertens. 2016 Feb;34(2):215-20. doi: 10.1097/HJH.0000000000000786.

PMID:
26599222
12.

Estimation of total kidney volume in autosomal dominant polycystic kidney disease.

Spithoven EM, van Gastel MD, Messchendorp AL, Casteleijn NF, Drenth JP, Gaillard CA, de Fijter JW, Meijer E, Peters DJ, Kappert P, Renken RJ, Visser FW, Wetzels JF, Zietse R, Gansevoort RT; DIPAK Consortium; DIPAK Consortium.

Am J Kidney Dis. 2015 Nov;66(5):792-801. doi: 10.1053/j.ajkd.2015.06.017. Epub 2015 Jul 31.

PMID:
26235803
13.

Modifiable factors associated with copeptin concentration: a general population cohort.

van Gastel MD, Meijer E, Scheven LE, Struck J, Bakker SJ, Gansevoort RT.

Am J Kidney Dis. 2015 May;65(5):719-27. doi: 10.1053/j.ajkd.2014.10.009. Epub 2014 Oct 31.

PMID:
25500109

Supplemental Content

Loading ...
Support Center